New drug cocktail aims to tackle Hard-to-Treat myeloma

NCT ID NCT05789303

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests a combination of four drugs—belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to treatment. The goal is to see if this mix can shrink tumors or slow the disease. About 83 adults will take part for up to 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (Blenrep), carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone
What this could lead to: If it works, this combination could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is an early Phase 2 trial with only 83 participants, so results may not apply to everyone. The drugs can cause side effects like eye problems, low blood counts, and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA RELAPSE MULTIPLE MYELOMA

Contacts and locations

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.